loading page

Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network
  • +3
  • Mitch Conover,
  • Yasser Albogami,
  • Jill Hardin,
  • Christian Reich,
  • Anna Ostropolets,
  • Patrick Ryan
Mitch Conover
Janssen Research and Development LLC

Corresponding Author:[email protected]

Author Profile
Yasser Albogami
King Saud University Department of Clinical Pharmacy
Author Profile
Jill Hardin
Janssen Research and Development LLC
Author Profile
Christian Reich
Real World Solutions
Author Profile
Anna Ostropolets
Columbia University Department of Biomedical Informatics
Author Profile
Patrick Ryan
Janssen Research and Development LLC
Author Profile


Introduction: Use observational methods to evaluate reliability of evidence generated by a study of the effect of glucagon-like peptide 1 receptor agonists (GLP-1RA) on chronic lower respiratory disease (CLRD) outcomes among type-2 diabetes mellites (T2DM) patients. Research Design and Methods: We independently reproduced a study comparing effects of GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP4-i) on CLRD outcome among patients with T2DM and prior CLRD. We reproduced inputs and outputs using the original study data (national administrative claims) and evaluated robustness to alternate design/analysis decisions. To evaluate generalizability, we applied the protocol and meta-analyzed across a research network including diverse array of populations and data sources. We also produced additional analyses evaluating individual drugs within the GLP-1RA class. Results: We confirmed alignment of study inputs and outputs and closely reproduced effect estimates and sensitivity analyses. Adjusted effect estimates were robust to empirical calibration. Network meta-analysis confirmed original findings, but indicated weaker effects than originally published. Meta-analyzing drugs within the GLP-1RA class against DPP4-I provided some evidence that effects vary within the GLP-1RA class, indicating stronger effects for exenatide and weaker effects of dulaglutide. Conclusions: This study supports the reliability of the original study by 1) confirming the findings in a range of alternate databases and populations 2) demonstrating effects for multiple drugs within the GLP-1RA class, and 3) independently confirming the reproducibility original study and its findings. We propose that clinicians treating patients with T2DM and a history of CLRD consider GLP-1RA in absence of strong motivating reasons to select another therapy.
07 Feb 2024Assigned to Editor
07 Feb 2024Submission Checks Completed
07 Feb 2024Reviewer(s) Assigned
01 Mar 2024Review(s) Completed, Editorial Evaluation Pending